Stocks Screener

Specify a stock or a cryptocurrency in the search bar to get a summary

Internet Computer ICP
Bitcoin Cash BCH
Litecoin LTC
Field stub for analysis

Clinuvel Pharmaceuticals Ltd

CLVLY
Current price
9.27 USD 0 USD (0.00%)
Last closed 14.2 AUD
ISIN AU000000CUV3
Sector Healthcare
Industry Biotechnology
Exchange AU
Capitalization 728 640 405 AUD
Yield for 12 month -11.19 %
1Y
3Y
5Y
10Y
15Y
CLVLY
21.11.2021 - 28.11.2021

Clinuvel Pharmaceuticals Limited, a biopharmaceutical company, focuses on developing and commercializing treatments for patients with genetic, metabolic, systemic, and life-threatening disorders in Australia, Europe, the United States, Switzerland, and internationally. Its lead drug candidate is SCENESSE, a systemic photoprotective drug for the prevention of phototoxicity in adult patients with erythropoietic protoporphyria (EPP). The company's pipeline products include CUV9900 and Parvysmelanotide (VLRX001), both alpha-melanocyte stimulating hormone analogue; and PRÉNUMBRA, a liquid injectable formulation of afamelanotide. It is also developing NEURACTHEL (ACTH), an adrenocorticotropic hormone to produce cortisol and enables the combat of stress and regulation of immune responses, maintenance of blood pressure, moderation of blood sugar, and regulation of metabolism. The company was incorporated in 1999 and is headquartered in Melbourne, Australia. Address: 535 Bourke Street, Melbourne, VIC, Australia, 3000

Check your investment idea

Find the best to beat the market
TSLA TSLA Tesla Motors
AAPL AAPL Apple
MSFT MSFT Microsoft

Analytics

WallStreet Target Price

42.09 AUD

P/E ratio

20.7429

Dividend Yield

0.37 %

Current Year

+88 391 693 AUD

Last Year

+78 510 850 AUD

Current Quarter

+55 510 442 AUD

Last Quarter

+32 334 943 AUD

Current Year

+78 285 890 AUD

Last Year

+50 711 884 AUD

Current Quarter

+50 207 664 AUD

Last Quarter

+16 961 320 AUD

Key Figures CLVLY

1 year
3 years
5 years
10 years
21.11.2021 - 28.11.2021
EBITDA 49 441 315 AUD
Operating Margin TTM 62.61 %
PE Ratio 20.7429
Return On Assets TTM 14.29 %
PEG Ratio
Return On Equity TTM 19.39 %
Wall Street Target Price 42.09 AUD
Revenue TTM 88 391 689 AUD
Book Value 4.06 AUD
Revenue Per Share TTM
Dividend Share 0.05 AUD
Quarterly Revenue Growth YOY 13.1 %
Dividend Yield 0.37 %
Gross Profit TTM 70 971 584 AUD
Earnings per share 0.7 AUD
Diluted Eps TTM 0.7 AUD
Most Recent Quarter II 2024
Quarterly Earnings Growth YOY 31.9 %
Profit Margin 40.41 %

Dividend Analytics CLVLY

Dividend growth over 5 years

150 %

Continuous growth

2 years

Payout Ratio 5 years average

8 %

Dividend History CLVLY

1 year
3 years
5 years
10 years
21.11.2021 - 28.11.2021
Forward Annual Dividend Rate 0.05
Ex Dividend Date 05.09.2024
Forward Annual Dividend Yield 0.34 %
Last Split Factor 1:10
Payout Ratio 7.16 %
Last Split Date 12.11.2010
Dividend Date

Stock Valuation CLVLY

1 year
3 years
5 years
10 years
21.11.2021 - 28.11.2021
Trailing PE 20.7429
Forward PE 20.4499
Enterprise Value Revenue 6.1567
Price Sales TTM 8.2433
Enterprise Value EBITDA 9.647
Price Book MRQ 3.5756

Financials CLVLY

1 year
3 years
5 years
10 years
15 years
Results 2019 Dynamics
* The data for this period has not yet been published

Technical indicators CLVLY

For 52 weeks

12.95 AUD 18.18 AUD
50 Day MA 14.42 AUD
Shares Short Prior Month
200 Day MA 14.86 AUD
Short Ratio
Shares Short
Short Percent